Abstracts tagged "Disease Activity and juvenile dermatomyositis"

Abstract Number: 419 • 2015 ACR/ARHP Annual Meeting
Development and Preliminary Validation of a New Composite Disease Activity Measure for Juvenile Dermatomyositis
Alessandro Consolaro¹, Giulia Camilla Varnier¹, Cristina Ferrari¹, Jaime De Inocencio², Adele Civino³, Marija Jelusic-Drazic⁴, Elena Tsitsami⁵, Jelena Vojinovic⁶, Balahan Makay⁷, Graciela Espada⁸, Clara Malattia¹, Susan Maillard⁹, Alberto Martini¹, Clarissa Pilkington¹⁰, Angelo Ravelli^1,11 and Kiran Nistala¹², ¹Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ²Hospital 12 de Octubre, Madrid, Spain, ³Ospedale Cardinale G. Panico, Tricase, Italy, ⁴University Hospital Center, Zagreb, Croatia, ⁵First Department of Pediatrics, Athens University Medical School, Athens, Greece, ⁶Faculty of Medicine, University of Nis, Nis, Serbia, ⁷Pediatric Rheumatology, Eylul University, Izmir, Turkey, ⁸Rheumatology Section, Childrens Hosp Ricardo Gutierrez, Buenos Aires, Argentina, ⁹Paediatric Rheumatology, Great Ormond Street Hospital NHS Foundation Trust for Children, London, United Kingdom, ¹⁰Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ¹¹University of Genova, Genova, Italy, ¹²Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Evaluation of the level of disease activity is a fundamental component of the clinical assessment of children with JDM. The global tools that are currently available for the assessment of the overall disease activity in JDM are centered on physician’s evaluation, neglecting parent’s or child’s perception. Furthermore, these instruments are lengthy and complex. There remains the need for a concise and easily administered tool that provides an absolute measure of disease activity for use in future trials in JDM. Aim of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].